Acute dyslipoproteinemia induced by interleukin-2: Lecithin: Cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 5, 1997, Pages 1572-1581

  Kwong, Linda K ^b   Ridinger, David N ^b   Bandhauer, Michael ^b   Ward, John H ^b   Samlowski, Wolfram E ^b   Iverius, Per Henrik ^b   Pritchard, Haydn ^b   Wilson, Dana E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CHOLESTASIS; CHOLESTEROL METABOLISM; DOSE RESPONSE; DRUG EFFECT; DYSLIPOPROTEINEMIA; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REGULATION; HUMAN; HYPOCHOLESTEROLEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; PRIORITY JOURNAL;

EID: 0030906904     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.5.1572     Document Type: Article

References (52)

1. Rosenberg SA. 1988 Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott; 217-257.
2. Rosenberg SA, Lotze MT, Muul LM, et al. 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 316:889-897.
3. Kovacs JA, Baseler M, Dewar RJ, et al. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med. 332:567-572.
4. Fisher B, Keenan AM, Garra BS, et al. 1989 Interleukin-2 induces a profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol. 7:1852-1862.
5. Malmendier CL, Lontie J-F, Sculier JP, Dubois DY. 1988 Modification of plasma lipids, lipoproteins, and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis. 73:173-180.
6. Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. 1989 Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins. J Clin Oncol. 7:1573-1577.
7. Rosenzweig IB, Wiebe DA, Hank JA, et al. 1990 Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy. 2:193-198.
8. Nimer SD, Champlin RE, Golde DW. 1988 Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA. 260:3297-3300.
9. Motoyoshi K, Takaku F. 1989 Serum cholesterol-lowering activity of human monocytic colony-stimulating factor. Lancet. 2:326-327.
10. Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA. 1988 Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 48:5864-5867.
11. NHBLI, NIH. 1974 Manual of laboratory operations. Lipid Research Clinics Program, vol 1. DHEW publication 75-628. Washington DC: US Government Printing Office.
12. Ames BN, Dubin DT. 1960 The role of polyaminines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem. 235:769-775.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951 Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265-75.
14. Chung BH, Wilkinson T, Geer JC, Segrest JP. 1980 Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res. 21:284-291.
15. Sata T, Estrich DL, Wood PDS, Kinsell LW. 1970 Evaluation of gel chromatography for lipoprotein fractionation. J Lipid Res. 11:331-340.
16. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. 1983 Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 24:886-898.
17. Laemmli UN. 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-685.
18. Frohlich J, McLeod R, Pritchard PH, Fesmire J, McConathy W. 1988 Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. Metabolism. 37:3-8.
19. Galfré G, Milstein C. 1981 Production of antibodies. Methods Enzymol. 73:3-46.
20. Nakane PK, Kawaoi A. 1974 Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem. 22:1084-1091.
21. Forte TM, Nordhausen RW. 1986 Electron microscopy of negatively stained lipoproteins. Methods Enzymol. 128:442-457.
22. Iverius PH, Östlund-Lindqvist AM. 1986 Preparation, characterization, and measurement of lipoprotein lipase. Methods Enzymol. 129:691-704.
23. Hata A, Ridinger DN, Sutherland SD, et al. 1992 Missense mutations in exon 5 of the human lipoprotein lipase gene. J Biol Chem. 267:20132-20139.
24. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. 1991 A frameshift mutation in the human apolipoprotein A-1 gene causes high density lipoprotein deficiency, partial lecithin:cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 87:371-376.
25. Dobiasova M. 1983 Lecithin:cholesterol acyltransferase and the regulation of endogenous cholesterol transport. Adv Lipid Res. 20:107-144.
26. Longwood CR., Knopf A, Flint RF, Schuchert C, Dunbar CO, eds. 1937 Outlines of geology. New York: Wiley and Sons; 244.
27. Torsvik H, Solaas MH, Gjone E. 1970 Serum lipoproteins in plasma lecithin: cholesterol acyltransferase deficiency studied by electron microscopy. Clin Genet. I:139-150.
28. Forte T, Norum KR, Glomset JA, Nichols AV. 1971 Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: structure of low density and high density lipoproteins as revealed by electron microscopy. J Clin Invest. 50:1141-1148.
29. Sabesin SM. 1982 Cholestatic lipoproteins - their pathogenesis and significance. Gastroenterology. 83:704-709.
30. Lotze MT, Matory YL, Rayner AA, et al. 1986 Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 58:2764-2772.
31. Norum KR, Gjone E, Glomset JA. 1989 Familial lecithin:cholesterol acyltransferase deficiency, including fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle, eds. The metabolic basis of inherited disease. New York: McGraw-Hill; 1181-1194.
32. Glomset JA, Norum KR, King W. 1970 Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: lipid composition and reactivity in vitro. J Clin Invest. 49:1827-1837.
33. Norum KR, Glomset JA, Nichols AV, Forte T. 1971 Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: physical and chemical studies of low and high density lipoproteins. J Clin Invest. 50:1131-1140.
34. Breckenridge WC, Little JA, Alaupovic P, et al. 1982 Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45:161-179.
35. Little JA, Connelly PW. 1986 Familial hepatic lipase deficiency. In: Angel A, Frolich J, eds. Lipoprotein deficiency syndromes. New York: Plenum Press; 000-000.
36. Goldberg IJ, Mazlen RG, Rubenstein A, et al. 1985 Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism. 34:832-835.
37. Goldberg IJ, Le N-A, Paterniti JR, Ginsberg HN, Lindgren FT, Brown WV. 1982 Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest. 70:1184-1192.
38. Jahn CE, Schaefer EJ, Taam LA, et al. 1985 Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 89:1266-1278.
39. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. 1989 Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 9:319-325.
40. Demant T, Carlson LA, Holmquist L, et al. 1988 Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 29:1603-1611.
41. Breslow JL. 1989 Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle, eds. The metabolic basis of inherited disease, 6th Ed. New York: McGraw-Hill; 1251-1266.
42. Millwe JP. 1990 Dyslipoproteinemia of liver disease. Baillieres Clin Endocrinol Metab. 4:807-832.
43. Ehnholm C, Aho K, Huttenen JK, et al. 1982 Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis. 2:68-73.
44. Kurzrock R, Rhode MF, Quesada JR, et al. 1986 Recombinant (γ) interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med. 164:1093-1101.
45. Cabana VG, Siegel JN, Sabesin SM. 1989 Effects of acute phase response on the concentrtion and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 30:39-49.
46. Cowett R. 1986 Utilization of glucose during total parenteral nutrition. In: Lebenthal E, ed. Total parenteral nutrition. New York: Raven Press; 17-27.
47. Becker DJ. 1986 Parenteral nutrition and hyperglycemia. In: Lebenthal H, ed. Total parenteral nutrition. New York: Raven Press; 445-450.
48. Forte TM, Genzel-Boroviczeny O, Austin MA, et al. 1989 Effect of total parenteral nutrition with intravenous fat on lipids and high density lipoprotein heterogeneity in neonates. J Parenter Enteral Nutr. 13:490-500.
49. Suzuki K, Hara M, Kitani A, et al. 1990 Augmentation of LDL receptor activities on lymphocytes by interleukin-2 and anti-CD3 antibody: a flow cytometric analysis. Biochim Biophys Acta. 1042:352-358.
50. Vitols S, Gahrton G, Öst Å, Peterson C. 1984 Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 63:1186-1193.
51. Ginsberg H, Goldberg IJ, Wang-Iverson P, et al. 1983 Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis. 3:233-241.
52. Budd D, Ginsberg H. 1986 Hypocholesterolemia and acute myelogenous leukemia. Cancer. 58:1361-1365.